BioLife Solutions, Inc. Aktie News

The CFO sold 30,000 shares for $771,600. This transaction represented 16.4% of Wichterman's direct holdings, reducing his direct stake to 152,769 shares.

New conference and laboratory facility to showcase the company's product portfolio and serve as a research and training hub to advance biopreservation and cell processing innovation BOTHELL, Wash. , Nov. 20, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today anno...

BOTHELL, Wash. , Nov. 17, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS ), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced that management will participate in the following investor conferences during November and December: Raymond James Napa Small Cap Symposium November 17, 2025 Napa Valley at The ...

BioLife Solutions, Inc. ( BLFS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Troy Wichterman - Chief Financial Officer Roderick de Greef - CEO & Chairman Conference Call Participants Paul Knight - KeyBanc Capital Markets Inc., Research Division Matthew Stanton - Jefferies LLC, Research Division Steven Etoch - Stephens Inc., Research Division Brendan Smith - TD Cowen,...

Cell Processing revenue of $25.4 million, up 33% over Q3 2024 GAAP gross margin of 62%  and non-GAAP adjusted gross margin of 64% GAAP net income of $0.6 million and non-GAAP adjusted EBITDA of $7.8 million or 28% of revenue Raises 2025 full-year Cell Processing revenue guidance to $93.0 million - $94.0 million; Full-year total revenue guidance to $95.0 - $96.0 million, adjusted for the recent ...

BOTHELL, Wash. , Oct. 23, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025.

BOTHELL, Wash. , Oct. 7, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools for the cell and gene therapy ("CGT") market, announces the sale of SAVSU Cleo Technologies, LLC.

After multiple acquisitions and significant dilution of shareholders, BioLife shed two freezer businesses which it couldn't get going. Focusing mostly on its core biopreservation media business is putting BLFS on much sounder footing, as it generates the highest margins and the company has a competitive advantage. This is already paying off with cash flow steadily increasing.